Changes of ticagrelor formulary tiers in the USA: Targeting private insurance providers away from government-funded plans

Victor L. Serebruany, James J. Dinicolantonio

Research output: Contribution to journalArticle

Abstract

Context: Ticagrelor (Brilinta®) is a new oral reversible antiplatelet agent approved by the FDA in July 2011 based on the results of the PLATO (Platelet Inhibition and Patient Outcomes) trial. However, despite very favorable and broad indications, the current clinical utilization of ticagrelor is woefully small. Objective: We aimed to compare ticagrelor formulary tiers for major private (n = 8) and government-funded (n = 4) insurance providers for 2012-2013. Results: Over the last year, ticagrelor placement improved, becoming a preferred drug (from Tier 3 in 2012 to Tier 2 in 2013) for Medco, moving from Tier 4 (with a prior approval requirement) to Tier 3 (no prior approval) for the United Health Care Private Plan and achieving Tier 3 status for Apex in 2013. In contrast, ticagrelor placement did not improve for New York Medicaid, retaining Tier 3 status. In addition, many Medicare Part D formularies have significantly worse coverage than most private plans. For example, Humana Medicare Part D has Tier 3 status requiring step therapy and quantity limits, SilverScript (CVS Caremark) Part D is Tier 3 and the American Association of Retired Persons (United Health Care) Medicare Part D is Tier 4 requiring prior approval. Conclusions: Ticagrelor formulary placement is significantly better for most private providers than for government-funded plans, which may possibly be due to the selective targeting of private insurance providers and the simultaneous avoidance of government-funded plans.

Original languageEnglish (US)
Pages (from-to)187-190
Number of pages4
JournalCardiology
Volume126
Issue number3
DOIs
StatePublished - Oct 2013

Fingerprint

Formularies
Insurance
Medicare Part D
Delivery of Health Care
Platelet Aggregation Inhibitors
Medicaid
Ticagrelor
Blood Platelets
Pharmaceutical Preparations

Keywords

  • Antiplatelet agents
  • Government funding
  • Private insurance
  • Ticagrelor formulary tiers

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Changes of ticagrelor formulary tiers in the USA : Targeting private insurance providers away from government-funded plans. / Serebruany, Victor L.; Dinicolantonio, James J.

In: Cardiology, Vol. 126, No. 3, 10.2013, p. 187-190.

Research output: Contribution to journalArticle

Serebruany, Victor L. ; Dinicolantonio, James J. / Changes of ticagrelor formulary tiers in the USA : Targeting private insurance providers away from government-funded plans. In: Cardiology. 2013 ; Vol. 126, No. 3. pp. 187-190.
@article{34b051c090fe4a029e064ad704eaa8ed,
title = "Changes of ticagrelor formulary tiers in the USA: Targeting private insurance providers away from government-funded plans",
abstract = "Context: Ticagrelor (Brilinta{\circledR}) is a new oral reversible antiplatelet agent approved by the FDA in July 2011 based on the results of the PLATO (Platelet Inhibition and Patient Outcomes) trial. However, despite very favorable and broad indications, the current clinical utilization of ticagrelor is woefully small. Objective: We aimed to compare ticagrelor formulary tiers for major private (n = 8) and government-funded (n = 4) insurance providers for 2012-2013. Results: Over the last year, ticagrelor placement improved, becoming a preferred drug (from Tier 3 in 2012 to Tier 2 in 2013) for Medco, moving from Tier 4 (with a prior approval requirement) to Tier 3 (no prior approval) for the United Health Care Private Plan and achieving Tier 3 status for Apex in 2013. In contrast, ticagrelor placement did not improve for New York Medicaid, retaining Tier 3 status. In addition, many Medicare Part D formularies have significantly worse coverage than most private plans. For example, Humana Medicare Part D has Tier 3 status requiring step therapy and quantity limits, SilverScript (CVS Caremark) Part D is Tier 3 and the American Association of Retired Persons (United Health Care) Medicare Part D is Tier 4 requiring prior approval. Conclusions: Ticagrelor formulary placement is significantly better for most private providers than for government-funded plans, which may possibly be due to the selective targeting of private insurance providers and the simultaneous avoidance of government-funded plans.",
keywords = "Antiplatelet agents, Government funding, Private insurance, Ticagrelor formulary tiers",
author = "Serebruany, {Victor L.} and Dinicolantonio, {James J.}",
year = "2013",
month = "10",
doi = "10.1159/000353810",
language = "English (US)",
volume = "126",
pages = "187--190",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "3",

}

TY - JOUR

T1 - Changes of ticagrelor formulary tiers in the USA

T2 - Targeting private insurance providers away from government-funded plans

AU - Serebruany, Victor L.

AU - Dinicolantonio, James J.

PY - 2013/10

Y1 - 2013/10

N2 - Context: Ticagrelor (Brilinta®) is a new oral reversible antiplatelet agent approved by the FDA in July 2011 based on the results of the PLATO (Platelet Inhibition and Patient Outcomes) trial. However, despite very favorable and broad indications, the current clinical utilization of ticagrelor is woefully small. Objective: We aimed to compare ticagrelor formulary tiers for major private (n = 8) and government-funded (n = 4) insurance providers for 2012-2013. Results: Over the last year, ticagrelor placement improved, becoming a preferred drug (from Tier 3 in 2012 to Tier 2 in 2013) for Medco, moving from Tier 4 (with a prior approval requirement) to Tier 3 (no prior approval) for the United Health Care Private Plan and achieving Tier 3 status for Apex in 2013. In contrast, ticagrelor placement did not improve for New York Medicaid, retaining Tier 3 status. In addition, many Medicare Part D formularies have significantly worse coverage than most private plans. For example, Humana Medicare Part D has Tier 3 status requiring step therapy and quantity limits, SilverScript (CVS Caremark) Part D is Tier 3 and the American Association of Retired Persons (United Health Care) Medicare Part D is Tier 4 requiring prior approval. Conclusions: Ticagrelor formulary placement is significantly better for most private providers than for government-funded plans, which may possibly be due to the selective targeting of private insurance providers and the simultaneous avoidance of government-funded plans.

AB - Context: Ticagrelor (Brilinta®) is a new oral reversible antiplatelet agent approved by the FDA in July 2011 based on the results of the PLATO (Platelet Inhibition and Patient Outcomes) trial. However, despite very favorable and broad indications, the current clinical utilization of ticagrelor is woefully small. Objective: We aimed to compare ticagrelor formulary tiers for major private (n = 8) and government-funded (n = 4) insurance providers for 2012-2013. Results: Over the last year, ticagrelor placement improved, becoming a preferred drug (from Tier 3 in 2012 to Tier 2 in 2013) for Medco, moving from Tier 4 (with a prior approval requirement) to Tier 3 (no prior approval) for the United Health Care Private Plan and achieving Tier 3 status for Apex in 2013. In contrast, ticagrelor placement did not improve for New York Medicaid, retaining Tier 3 status. In addition, many Medicare Part D formularies have significantly worse coverage than most private plans. For example, Humana Medicare Part D has Tier 3 status requiring step therapy and quantity limits, SilverScript (CVS Caremark) Part D is Tier 3 and the American Association of Retired Persons (United Health Care) Medicare Part D is Tier 4 requiring prior approval. Conclusions: Ticagrelor formulary placement is significantly better for most private providers than for government-funded plans, which may possibly be due to the selective targeting of private insurance providers and the simultaneous avoidance of government-funded plans.

KW - Antiplatelet agents

KW - Government funding

KW - Private insurance

KW - Ticagrelor formulary tiers

UR - http://www.scopus.com/inward/record.url?scp=84888167724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888167724&partnerID=8YFLogxK

U2 - 10.1159/000353810

DO - 10.1159/000353810

M3 - Article

C2 - 24030166

AN - SCOPUS:84888167724

VL - 126

SP - 187

EP - 190

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 3

ER -